Arcadia Biosciences (NASDAQ:RKDA) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued on Monday. The brokerage set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Stock Up 2.9 %

Shares of NASDAQ RKDA opened at $2.81 on Monday. The stock’s 50 day moving average price is $2.81 and its two-hundred day moving average price is $2.71. Arcadia Biosciences has a 52-week low of $1.85 and a 52-week high of $3.93. The stock has a market capitalization of $3.82 million, a P/E ratio of -0.56 and a beta of 1.34.

Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.27 by ($0.49). The firm had revenue of $1.31 million for the quarter, compared to analyst estimates of $0.95 million. Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. During the same period in the prior year, the company posted ($2.64) earnings per share. On average, analysts anticipate that Arcadia Biosciences will post -1.7 EPS for the current year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.